Previous 10 | Next 10 |
2024-02-15 12:04:40 ET More on Cardiol Therapeutics Seeking Alpha’s Quant Rating on Cardiol Therapeutics Historical earnings data for Cardiol Therapeutics Financial information for Cardiol Therapeutics Read the full article on Seeking Alpha For...
2024-02-15 10:00:00 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Communication Services, Info ...
Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study This is a Designated News Release. Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "),...
Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024 Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life s...
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatm...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Cardiol Therapeutics Inc. (CRDL) is expected to report for Q3 2023
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatme...
2023-10-20 17:11:41 ET More on Cardiol Therapeutics Seeking Alpha’s Quant Rating on Cardiol Therapeutics Historical earnings data for Cardiol Therapeutics Financial information for Cardiol Therapeutics For further details see: Cardiol Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
Cardiol Therapeutics Inc. Website:
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
2024-06-26 06:30:06 ET B. Riley analyst issues BUY recommendation for CRDL on June 26, 2024 04:52AM ET. CRDL was trading at $2.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations . ...
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...